BEACON — Biomarkers for Early Assessment, Cancer detection, and Outcome Navigation — is a Fred Hutch Cancer Center initiative advancing research in early cancer detection and prevention.
By integrating biomarker discovery with cutting-edge computational and molecular tools, BEACON aims to improve the accuracy and accessibility of cancer screening.
Fred Hutch leads several NCI-sponsored programs — including the Early Detection Research Network, Liquid Biopsy Consortium, and Cancer Screening Registry Network — and serves as a national hub for biomarker innovation.
BEACON unites scientists across disciplines to drive breakthroughs that enable earlier, more precise cancer detection and better prevention strategies.
The Etzioni Lab is an integral partner in the BEACON (Biomarkers for Early Assessment, Cancer detection, and Outcome Navigation) initiative at Fred Hutch, with Dr. Ruth Etzioni serving on BEACON’s Executive Committee.
Bringing together experts in biostatistics, computer science, and health economics, the Etzioni Lab provides BEACON with advanced modeling and data science expertise to evaluate and optimize cancer diagnostics, including novel biomarkers, imaging tools, and AI-based detection methods.
The lab’s pioneering work in simulation modeling, diagnostic performance evaluation, and multi-cancer early detection directly supports BEACON’s mission to improve the accuracy and clinical impact of cancer detection strategies.